Ryan Haumschild, PharmD, MS, MBA, CPEL

This episode applies the discussion to two patients with HER2-mutant non–small cell lung cancer.

This episode maps the early weeks of oral zongertinib and the real-world factors that threaten them.

This episode addresses central nervous system metastases, which the panel notes may affect nearly half of patients with HER2-mutant non–small cell lung cancer.

This episode focuses on the safety profile of zongertinib and what it takes to keep patients on therapy.

This episode makes the case for moving HER2-targeted therapy into the first-line setting.

This episode follows the path from a positive HER2 result to a patient starting treatment.

This episode takes up the practical mechanics of molecular testing in community oncology, beginning with turnaround time.

This episode opens with a distinction that matters more in lung cancer than many oncologists expect.